Inhibiting the fibroblast growth factor 2 and fibroblast growth factor receptor 1 (FGF2-FGFR1) signaling pathway reduced exosome secretion and sensitized leukemia cells to TKIs, indicating a potential therapeutic approach to counteract drug resistance [195]. The gene discussed is FGFR1; the disease is leukemia.